Impact of Premature Ovarian Failure on Mortality and Morbidity among Chinese Women

Wu, Xiaoyan; Cai, Hui; Kallianpur, Asha R.; Li, Honglan; Yang, Gong; Gao, Jing; Xiang, Yong Bing; Ji, Bu Tian; Yutang,; Wang, Zheng

doi:10.1371/journal.pone.0089597

Cited by 84 publications

(66 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At approximately age 50, female fertility begins to decline along with the continued depletion of the primordial follicle pool until the occurrence of menopause [3]. However, certain pathological conditions, such as endometriosis, myomas, and chemotherapy drugs, are thought to cause premature ovarian failure [4,5,6]. …”

Section: Introductionmentioning

confidence: 99%

Ovarian Germline Stem Cells (OGSCs) and the Hippo Signaling Pathway Association with Physiological and Pathological Ovarian Aging in Mice

Zhou

Zheng

et al. 2015

Cell Physiol Biochem

View full text Add to dashboard Cite

Background: The Hippo signaling pathway plays fundamental roles in stem cell maintenance in a variety of tissues and has thus implications for stem cell biology. Key components of this recently discovered pathway have been shown to be associated with primordial follicle activation. However, whether the Hippo signaling pathway plays a role in the development of Ovarian Germline Stem Cells (OGSCs) during physiological and pathological ovarian aging in mice is unknown. Methods: Mice at the age of 7 days (7D), or of 2, 10, or 20 months (2M, 10M, 20M) and mice at 2M treated with TPT and CY/BUS drugs were selected as physiological and pathological ovarian aging models, respectively. Immunohistochemistry was used to assess the development of follicles, and the co-localization of genes characteristic of OGSCs with MST1, LATS2 and YAP1 was assessed by immunofluorescence, western blotting and real-time PCR methods. Results: The Hippo signal pathway and MVH/OCT4 genes were co-expressed in the mouse ovarian cortex. The level and co-localization of LATS2, MST1, MVH, and OCT4 were significantly decreased with increased age, but YAP1 was more prevalent in the mouse ovarian cortex of 2M mice than 7D mice and was not observed in 20M mice. Furthermore, YAP1, MVH, and OCT4 were gradually decreased after TPT and CY/BUS treatment, and LATS2 mRNA and protein up-regulation persisted in TPT- and CY/BUS-treated mice. However, the expression of MST1 was lower in the TPT and CY/BUS groups compared with the control group. In addition, pYAP1 protein showed the highest expression in the ovarian cortexes of 7D mice compared with 20M mice, and the value of pYAP1/YAP1 decreased from 7D to 20M. Moreover, pYAP1 decreased in the TPT- and CY/BUS-treated groups, but the value of pYAP1/YAP1 increased in these groups. Conclusion: Taken together, our results show that the Hippo signaling pathway is associated with the changes that take place in OGSCs during physiological and pathological ovarian aging in mice. Thus, the Hippo signaling pathway may be involved in the development schedule of OGSCs.

show abstract

Section: Introductionmentioning

confidence: 99%

Ovarian Germline Stem Cells (OGSCs) and the Hippo Signaling Pathway Association with Physiological and Pathological Ovarian Aging in Mice

Zhou

Zheng

et al. 2015

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…Wu et al [39] have shown a decreased risk of breast cancer in POI women. Furthermore, Bösze et al [40] have followed women with POI for 40 years.…”

Section: Follow-up Of Hrt In Adolescents and Young Womenmentioning

confidence: 99%

Use of Hormone Replacement in Females with Endocrine Disorders

Christin-Maître¹

2017

Horm Res Paediatr

View full text Add to dashboard Cite

Hormone replacement therapy (HRT) is necessary in adolescents with primary ovarian insufficiency (POI) in order to avoid estrogen deficiency. The goal of this minirewiew is to present the different types of estrogens (17β-estradiol, estradiol valerate, ethinyl estradiol, and combined equine estrogens) as well as the different types of progestins available. In order to choose among the different types of HRTs, the features of each regimen are being discussed as well as their risks and their respective benefits. The differences between oral combined contraceptive pills and a dissociated regimen containing estrogen and progestins are emphasized. The different effects of HRTs, mainly on feminization, growth spurt, bone mass as well as cardiovascular risk, and the follow-up of these young patients are presented. HRT in adolescents and young adults with estrogen deficiency is necessary and should be continued until the age of natural menopause. Studies have so far essentially included children or adolescents with Turner syndrome. Therefore, studies on HRT including patients with POI and a normal karyotype are necessary.

show abstract

“…Hormone replacement therapy (HRT) is the most effective way to treat the immediate symptoms of estrogen deficiency and prevent long‐term sequelae. For most women experiencing an early or premature menopause, HRT presents minimal risks and there are very few absolute contraindications to its use …”

Section: Introductionmentioning

confidence: 99%

Hormone replacement therapy following treatment of gynaecological malignancies

Richardson

Ayres

Cust

et al. 2019

The Obstetric & Gynaecologis

View full text Add to dashboard Cite

Key content Approximately 21 000 women in the UK were diagnosed with a gynaecological malignancy in 2015; although most of these malignancies occurred in postmenopausal women, 30–40% present in premenopausal or perimenopausal women. Management typically involves surgery and/or chemotherapy and/or radiotherapy, which in younger women may result in an induced menopause. Many women struggle with both the immediate symptoms and the long‐term consequences of estrogen deficiency, all of which are debilitating and compromise the quality and quantity of life, in addition to the cancer diagnosis and treatment. These patients represent a complex group and most units in the UK do not have easy access to menopause specialists. Gynaecologists may be reluctant to prescribe hormone replacement therapy (HRT) to these women; clinicians involved in the care of these women must appreciate when HRT is and is not contraindicated. Learning objectives To understand the safety of HRT in women who have undergone treatment for endometrial, ovarian, cervical, vulval or vaginal malignancies, with particular emphasis on the type, stage and grade of cancer. To establish an evidence‐based approach to the management of menopausal symptoms using HRT in women who have previously been treated for a gynaecological malignancy. To appreciate the role of non‐hormonal alternatives to HRT in these women. Ethical issues How to balance the known benefits of HRT against the potential risks, when evidence is limited in women who have undergone treatment for a gynaecological malignancy.

show abstract

Impact of Premature Ovarian Failure on Mortality and Morbidity among Chinese Women

Cited by 84 publications

References 39 publications

Ovarian Germline Stem Cells (OGSCs) and the Hippo Signaling Pathway Association with Physiological and Pathological Ovarian Aging in Mice

Ovarian Germline Stem Cells (OGSCs) and the Hippo Signaling Pathway Association with Physiological and Pathological Ovarian Aging in Mice

Use of Hormone Replacement in Females with Endocrine Disorders

Hormone replacement therapy following treatment of gynaecological malignancies

Contact Info

Product

Resources

About